COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis (He-ppi)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01524757
Recruitment Status : Unknown
Verified January 2012 by Maastricht University Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : February 2, 2012
Last Update Posted : February 2, 2012
Annadal stichting
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:

Hereditary Hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload causing damage of different important organs like heart, liver, pancreas and joints. Complications and symptoms can regress by intensive treatment reducing the iron overload stores.Different genes have been identified playing a role in the pathophysiology of iron overload. A clinically important HFE gene mutation is the C282Y, located on chromosome 6. Phlebotomy is currently the standard therapy which consists of removal of 500 ml whole blood weekly, representing a loss of 250 mg iron. In naive patients between 20 to 100 phlebotomies are required to reduce the serum ferritine levels to 50 μg/L. Thereafter, a lifelong maintenance therapy of 3 to 6 phlebotomies yearly is needed.

For absorption, dietary iron ( 70%) is reduced by gastric acid form the ferric (Fe3+) to the ferrous form (Fe2+). Recently, in an observational open study, Hutchinson et al. found that HH patients treated with proton pump inhibitors (PPI) needed fewer phlebotomies, resulting in a drop of 2.5 (SEM 0.25) to 0.5 (SEM 0.25) liter per year.

Research question: The primary objective is to determine the effectiveness and cost effectiveness of PPI's compared to standard phlebotomy therapy in the prevention of iron overload in HH patients.

Multi-center trial in two hospitals in the South of Limburg (Atrium medical Center, Maastricht university medical center ) and hospital in Belgium (University Hospital Gasthuisberg). The study will be conducted in randomised double blind manner. The follow up will be one year.

Patients are randomized either for the group receiving a PPI or a placebo. Every 2 month the ferritin level is measured and decided if the patient need a phlebotomy (Ferritin >100 µg/L).

Condition or disease Intervention/treatment Phase
Hemochromatosis Drug: Pantoprazole Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis
Study Start Date : March 2012
Estimated Primary Completion Date : August 2013
Estimated Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: pantoprazol Drug: Pantoprazole
pantoprazole 40mg 1dd1; 12 months

Placebo Comparator: placebo Drug: Pantoprazole
pantoprazole 40mg 1dd1; 12 months

Primary Outcome Measures :
  1. the total number of phlebotomies for the group taking PPI treatment compared to the group taking placebo will be the primary endpoint of the study. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. number of participants with side effects [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hereditary hemochromatosis (HH), homozygous for C282Y, currently treated with phlebotomy as maintenance therapy for at least 12 months with ≥ 3 phlebotomies per year.
  • Ferritin level between 50-100 μg/L at start of the inclusion.
  • Age: 18 years- 60 years and weight > 50 kg.

Exclusion Criteria:

  • Patients receiving other therapies such as chelating therapy or forced dietary regimen.
  • Patients younger than 18 years.
  • HH patients with excessive overweight (BMI > 35).
  • Patients who are mentally incapacitated.
  • Women being pregnant or expecting/ planning to become pregnant during the one year period of the study.
  • Patients with a malignancy.
  • Patients already on PPI treatment.
  • Patients who experienced side effects of PPI's.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01524757

Layout table for location contacts
Contact: G Koek, dr +31-43-3875021
Contact: C Deursen Van, dr 31-45-5279639

Layout table for location information
University hospital Gasthuisberg
Leuven, Limburg, Belgium, 3000
Contact: David Cassiman, prof. dr.    +32 16344626   
Principal Investigator: David Cassiman, prof. dr.         
Atrium MC Parkstad
Heerlen, Limburg, Netherlands, 6440 AG
Contact: Cees Deursen, dr    +31-45-5279639   
Contact: Reggy Jaspers, drs    +31-43-3875021   
Principal Investigator: C Deursen, dr         
Maastricht university medical center
Maastricht, Limburg, Netherlands, 6202AZ
Contact: Reggy Jaspers, drs    +31-43-3875021   
Contact: Ger Koek, dr-    +31-43-3875021   
Principal Investigator: Ger Koek, dr         
Sponsors and Collaborators
Maastricht University Medical Center
Annadal stichting
Layout table for investigator information
Principal Investigator: G Koek, Dr Maastricht University Medical Center


Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maastricht University Medical Center Identifier: NCT01524757    
Other Study ID Numbers: NL3364409612
First Posted: February 2, 2012    Key Record Dates
Last Update Posted: February 2, 2012
Last Verified: January 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Proton Pump Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action